FDA approves Roche ’s Perjeta (pertuzumab) for adjuvant treatment of specific type of early breast cancer

Roche today announced the US Food and Drug Administration (FDA) has approved Perjeta ® (pertuzumab), in combination with Herceptin® (trastuzumab) and chemotherapy (the Perjeta-based regimen), for adjuvant (after surgery) treatment of HER2-positive early breast cancer (eBC) at high risk of recurrence.
Source: Roche Media News - Category: Pharmaceuticals Source Type: news